Hormonothérapie du cancer du sein
Tài liệu tham khảo
Beatson, 1896, On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases, Lancet, 104, 10.1016/S0140-6736(01)72307-0
Hahnel, 1971, Estrogen receptors in human breast cancer. 1- Methodology and characterization of receptors, Steroids, 18, 653, 10.1016/0039-128X(71)90029-8
Vilain, 1997, Ann Pathol, 17, 82
Elledge, 2000, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study, Int J Cancer, 89, 111, 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
Zafrani, 2000, High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases, Histopathology, 37, 536, 10.1046/j.1365-2559.2000.01006.x
Leers, 2000, A novel flow cytometric steroid hormone receptor assay for paraffin-embedded breast carcinomas: an objective quantification of the steroid hormone receptors and direct correlation to ploidy status and proliferative capacity in a single-tube assay, Hum Pathol, 31, 584, 10.1053/hp.2000.6700
Rhodes, 2000, Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening, J Clin Pathol, 53, 688, 10.1136/jcp.53.9.688
Collins, 2005, Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases, Am J Clin Pathol, 123, 16, 10.1309/HCF035N9WK40ETJ0
Andersen, 1989, Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer, Cancer, 64, 1901, 10.1002/1097-0142(19891101)64:9<1901::AID-CNCR2820640924>3.0.CO;2-W
Bezwoda, 1991, The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen, Cancer, 68, 867, 10.1002/1097-0142(19910815)68:4<867::AID-CNCR2820680432>3.0.CO;2-H
Chen, 1989, Selection of hormone-responsive advanced breast cancer with a cytoplasmic estrogen receptor assay. Analysis of 100 cases, Cancer, 63, 139, 10.1002/1097-0142(19890101)63:1<139::AID-CNCR2820630122>3.0.CO;2-J
De Laurentiis, 2005, A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer, Clin Cancer Res, 11, 4741, 10.1158/1078-0432.CCR-04-2569
Sainsbury, 2003, Ovarian ablation as a treatment for breast cancer, Surg Oncol, 12, 241, 10.1016/j.suronc.2003.11.002
Featherstone, 1999, Ultrasound localization of the ovaries for radiation-induced ovarian ablation, Clin Oncol (R Coll Radiol), 11, 393, 10.1053/clon.1999.9090
Hughes, 2004, Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study, Cancer, 101, 969, 10.1002/cncr.20481
Leung, 1991, Ovarian ablation failures by radiation: a comparison of two dose schedules, Br J Radiol, 64, 537, 10.1259/0007-1285-64-762-537
Sasco, 1996, Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy, Epidemiology, 7, 9, 10.1097/00001648-199601000-00003
Mignotte, 1998, Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération nationale des centres de lutte contre le cancer (FNCLCC), Int J Cancer, 76, 325, 10.1002/(SICI)1097-0215(19980504)76:3<325::AID-IJC7>3.0.CO;2-X
Kaufmann, 1988, Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer, Geburtshilfe Frauenheilkd, 48, 528, 10.1055/s-2008-1026532
Bundred, 2005, Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer, Cancer Invest, 23, 173, 10.1081/CNV-50480
Howell, 2005, Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials, Cancer, 104, 236, 10.1002/cncr.21163
Howell, 2004, Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial, J Clin Oncol, 22, 1605, 10.1200/JCO.2004.02.112
Valachis, 2010, Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials, Crit Rev Oncol Hematol, 73, 220, 10.1016/j.critrevonc.2009.03.006
Klijn, 2001, Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials, J Clin Oncol, 19, 343, 10.1200/JCO.2001.19.2.343
Boccardo, 1994, Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study, Ann Oncol, 5, 337, 10.1093/oxfordjournals.annonc.a058837
Mouridsen, 2003, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol, 21, 2101, 10.1200/JCO.2003.04.194
Gennatas, 2006, Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO), Tumori, 92, 13, 10.1177/030089160609200103
Early Breast Cancer Trialists’ Collaborative Group. Ovarian ablation for early breast cancer. Cochrane Database Syst Rev 2000; CD000485.
1996, Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer, J Natl Cancer Inst, 88, 1834, 10.1093/jnci/88.24.1834
1996, Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer, J Natl Cancer Inst, 88, 1543, 10.1093/jnci/88.21.1543
Delozier, 2000, Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération nationale des centres de lutte contre le cancer Breast Group, J Clin Oncol, 18, 3507, 10.1200/JCO.2000.18.20.3507
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60–2.
Coates, 2007, Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98, J Clin Oncol, 25, 486, 10.1200/JCO.2006.08.8617
Coombes, 2004, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med, 350, 1081, 10.1056/NEJMoa040331
Coombes, 2007, Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, Lancet, 369, 559, 10.1016/S0140-6736(07)60200-1
Mauriac, 2007, Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Ann Oncol, 18, 859, 10.1093/annonc/mdm001
Mouridsen, 2009, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer, N Engl J Med, 361, 766, 10.1056/NEJMoa0810818